Screener
Abbott ABT Diagnostic Products — Operating Earnings
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Net Sales to External Customers / Three Months Ended June 30, 2026 | Net Sales to External Customers / Three Months Ended June 30, 2025 | Cost of Products Sold / Three Months Ended June 30, 2026 | Cost of Products Sold / Three Months Ended June 30, 2025 | Research and Development / Three Months Ended June 30, 2026 | Research and Development / Three Months Ended June 30, 2025 | Selling, General, and Administrative / Three Months Ended June 30, 2026 | Selling, General, and Administrative / Three Months Ended June 30, 2025 | Operating Earnings / Three Months Ended June 30, 2026 | Operating Earnings / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Established Pharmaceuticals | $1,499 | $1,383 | $(650) | $(631) | $(48) | $(43) | $(419) | $(363) | $382 | $346 |
| Nutritional Products | 2,144 | 2,212 | (1,148) | (1,155) | (54) | (54) | (574) | (585) | 368 | 418 |
| Diagnostic Products | 3,092 | 2,173 | (1,532) | (1,224) | (268) | (154) | (793) | (423) | 499 | 372 |
| Medical Devices | 5,853 | 5,369 | (1,925) | (1,758) | (470) | (430) | (1,489) | (1,385) | 1,969 | 1,796 |
| Total | $12,588 | $11,137 | $(5,255) | $(4,768) | $(840) | $(681) | $(3,275) | $(2,756) | $3,218 | $2,932 |
| Other | 5 | 5 | ||||||||
| Net sales | $12,593 | $11,142 | ||||||||
| Corporate functions and plan benefit costs | (45) | (65) |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's diagnostic products — operating earnings?
- Abbott (ABT) reported diagnostic products — operating earnings of $499M in Q2 2026.
- How has Abbott's diagnostic products — operating earnings changed year-over-year?
- Abbott's diagnostic products — operating earnings increased by 34.1% year-over-year, from $372M to $499M.
- What is the long-term trend for Abbott's diagnostic products — operating earnings?
- Over 4 years (2021 to 2025), Abbott's diagnostic products — operating earnings has grown at a -27.4% compound annual growth rate (CAGR), from $6.26B to $1.74B.
- What does diagnostic products — operating earnings mean?
- The profit generated from the diagnostics segment after subtracting operating expenses from net sales. This is the primary measure of the segment's core operational profitability and efficiency.
Ask your AI about Abbott's diagnostic products — operating earnings.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude